Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin in moderately severe to severe Alzheimer's disease
NCT02431468Phase 2Completed
- Sponsor
- Synaptogenix, Inc.
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bryostatin-1 in Alzheimer's disease (AD), sponsored by Synaptogenix, Inc.. Started Nov 2015; status: completed.
02
Drugs
bryostatin-1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02431468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431468.